

Perspective on the Innovative Medicines Initiative 2 (IMI2)

Dr Ruxandra Draghia-Akli, MD PhD
Director Health
DG Research and Innovation
European Commission

IMI2 Open Info Day
Brussels, 30 September 2014



EU health
research

Inspiring collaboration

**IMI 2 is an integral
part of our
strategy for EU
health research**

Public-private partnerships
Investing together for next generation medicines and treatments

Public partnerships
Harnessing global expertise to fight poverty-related diseases

Global co-operation
One world, one team working to solve common health challenges

Collaborative research
Real-life solutions based on joint problem-solving



At the forefront



- 2003 EDCTP - 1st "Article 169 Initiative"
- 2008 IMI - 1st "Article 171 Initiative" at DG Research
- 2009 1st Joint Programming initiative on Alzheimer's
- 2010 Innovation Partnerships on Active & Healthy Ageing
- 2010/11 Large-scale international research initiatives on Epigenome/Blueprint, rare diseases...
- 2012 "SMEs for Innovation" call & 1st Innovation Inducement Prize

IMI 2 scope and objectives

- **IMI 2 will expand the scope of IMI 1 to cover the entire medical research and innovation value chain:**
 - Actively involve life science industries other than pharmaceuticals; for example the vaccine, the animal health or the biomedical imaging industry
- **Enable top quality research and innovations with great public health benefits and commercial possibilities**
- **Pave the way for the breakthrough vaccines, medicines and treatments which we will need in the near future:**
 - Develop new therapies for diseases with high unmet need, such as Alzheimer's disease, and limited market incentives, such as antimicrobial resistance

IMI 2 strategic research agenda

Priority Medicines for Europe and the World 2013 Update

Warren Kaplan, Veronika J. Wirtz,
Aukje Mantel-Teeuwisse, Pieter Stolk,
Béatrice Duthey, Richard Laing

9 July 2013



The right prevention and treatment
for the right patient at the right time

Strategic Research Agenda for
Innovative Medicines Initiative 2

**Aligned with
WHO priorities**

IMI 2 budget and funding

- **Budget from public and private partners: 3.27 Billion Euro; 1.638 Billion Euro EU contribution:**
 - Up to EUR 1 425 million to match EFPIA's contribution
 - Up to EUR 213 million to match additional contributions from other future Members or Associated Partners
- **All EU funding goes to SMEs, medium-sized industrial partners (annual sales less than €500 million), academia, patient organisations and regulatory agencies**
- **Simplified funding rates & reporting (aligned with H2020)**

How will IPR be handled?

Similarly to the first phase, IMI 2 will aim to:

- Promote knowledge creation together with its disclosure and exploitation
- Achieve a fair allocation of rights
- Reward innovation
- Achieve a broad participation of private and public entities

IP rules only depart from H2020 rules when required by the specific operating needs of IMI 2

IMI 2 aligned with Horizon 2020

- Rules for participation apply, except for derogations on IPR and eligibility for funding
- Simplifications in Horizon 2020 also apply to IMI 2 (funding rates, indirect cost!)
- Publication of calls on Participant Portal (and on IMI website)
- Search function includes IMI 2 topics



RESEARCH & INNOVATION

Participant Portal

European Commission > Research & Innovation > Participant Portal > Calls

HOME FUNDING OPPORTUNITIES HOW TO PARTICIPATE EXPERTS SUPPORT LOGIN REGISTER

Horizon 2020

Search Topics

Calls

Call Updates

Other EU Programmes 2014-2020

Research Fund for Coal & Steel

COSME

3rd Health Programme

Consumer Programme

FP7 & CIP Programmes 2007-2013

Calls

Call Updates

Other Funding Opportunities

Horizon 2020 Calls for Proposals

- Leadership in enabling and industrial technologies (LEIT)
- Access to risk finance
- Innovation in SMEs
- Societal Challenges**
- Health, demographic change and wellbeing
- Food security, sustainable agriculture and forestry, marine and maritime and inland water research
- Secure, clean and efficient energy
- Smart, green and integrated transport

- Status
- Forthcoming
 - Open
 - Closed

FILTER

Filters only programme and call titles and IDs, for extended search go to the [Search Topics page](#).

Sort by Title Call Id Planned Opening Date Deadline Date

Societal Challenges Personalising health and care H2020-PHC-2015-single-stage_RT D Deadlines: 24/02/2015 Opening Date: 30/07/2014	Societal Challenges Personalising health and care H2020-PHC-2015-two-stage Deadlines: 14/10/2014 Opening Date: 30/07/2014	Societal Challenges Personalising health and care H2020-PHC-2015-single-stage Deadlines: 21/04/2015 Opening Date: 30/07/2014
Societal Challenges Health Co-ordination Activities H2020-HCO-2015 Deadlines: 24/02/2015 Opening Date: 30/07/2014	Societal Challenges IM12 1st Call for Proposals 2014 H2020-JTI-IM12-2014-01 Deadlines: 12/11/2014 Opening Date: 09/07/2014	Industrial Leadership Horizon 2020 dedicated SME Instrument - Phase 2 2014 H2020-SMEINST-2-2014 Deadlines: 09/10/2014 17/12/2014 Opening Date: 03/03/2014
Industrial Leadership Horizon 2020 dedicated SME Instrument - Phase 1 2014 H2020-SMEINST-1-2014 Deadlines: 18/06/2014 24/09/2014 17/12/2014 Opening Date: 03/03/2014		



RESEARCH & INNOVATION

Participant Portal

European Commission > Research & Innovation > Participant Portal > Calls

HOME FUNDING OPPORTUNITIES HOW TO PARTICIPATE EXPERTS SUPPORT LOGIN REGISTER

Horizon 2020

Search Topics

Calls

Call Updates

Other EU Programmes 2014-2020

Research Fund for Coal & Steel

COSME

3rd Health Programme

Consumer Programme

FP7 & CIP Programmes 2007-2013

Calls

Call Updates

Other Funding Opportunities

1 Results

Keyword Search: SEARCH

If you don't find your topic, you can also use the [free text search](#).

- Status**
- Open
 - Closed
 - Forthcoming
- Sort by**
- Title
 - Call Id
 - Publication Date
 - Deadline Date

Topic: [Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus \(T1DM\):IMI2-2014-01-01](#)
Specific challenge: Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide

Call title: [IMI2 1st Call for Proposals 2014](#) **Status:** Open
Call identifier: [H2020-JTI-IMI2-2014-01](#) **Deadline:** 12-11-2014

In addition, **see all the open calls** of Marie Skłodowska-Curie actions (MSCA) and European Research Council (ERC) grants for individual researchers of any nationality and research teams. The MSCA grants include opportunities for companies and SMEs. **The MCSA and ERC grants are not restricted to specific topics.**

Quick finder for topics linked to H2020 cross-cutting priorities:

- [Cross-cutting Key-Enabling Technologies \(KETs\)](#)
- [ERA-NET](#)
- [Gender](#)
- [Contractual Public-Private Partnerships \(cPPPs\)](#)
- [International cooperation](#)
- [SME Instrument](#)
- [Social sciences and humanities](#)